CochlearHAM:OC5 +0.62%70 Market Cap is €4,688 Mil as of Jun. 28, 2026. GuruFocus rates HAM:OC5 with a GF Score™ of 70/100 and a GF Value™ of €187.78 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Cochlear ranks better than 93.66% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cochlear's share price for the quarter that ended in Dec. 2025 was €147.38. Cochlear's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 65 Mil. Therefore, Cochlear's market cap for the quarter that ended in Dec. 2025 was €9,638 Mil.
Cochlear's quarterly market cap
declined
from Dec. 2024 (€11,493 Mil) to Jun. 2025 (€10,882 Mil) and
declined
from Jun. 2025 (€10,882 Mil) to Dec. 2025 (€9,638 Mil).
Cochlear's annual market cap
increased
from Jun. 2023 (€9,145 Mil) to Jun. 2024 (€13,400 Mil) but then
declined
from Jun. 2024 (€13,400 Mil) to Jun. 2025 (€10,882 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cochlear's Enterprise Value for Today is €4,721 Mil.
Cochlear (HAM:OC5) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cochlear Market Cap Related Terms
Cochlear Market Cap Historical Data
* Premium members only.
The historical data trend for Cochlear's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cochlear's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Market Cap distribution charts can be found below:
* The bar in red indicates where Cochlear's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cochlear's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (HAM:OC5) has a Market Cap of €4,688 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cochlear and its competitors. According to the industry distribution chart, Cochlear ranks #55 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 6.3%.
Is Cochlear's Market Cap too high?
Cochlear's current Market Cap is €4,688 Mil. Based on the distribution chart, Cochlear ranks #55 out of 868 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #55 out of 868 companies for Market Cap. This places Cochlear in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 118.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 118.39, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 118.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current Market Cap is €4,688 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (HAM:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €187.78, compared to a current price of €71.24 — trading 62.1% below its estimated fair value. The current Market Cap is €4,688 Mil. Cochlear's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cochlear (HAM:OC5), the current Market Cap is €4,688 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (HAM:OC5) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of €71.24 is trading 62.1% below its estimated GF Value™ of €187.78.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for HAM:OC5:
Market Cap: €4,688 Mil
GF Value™: €187.78 vs. price of €71.24 (62.1% below fair value)
No single metric tells the full story. See the HAM:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
70GF Score
Get the complete analysis for HAM:OC5
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:OC5 has been successfully added to your 
